secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001753926-24-001422
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024
--------------------------------------------------------------------------------

- Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.
- Net loss $5.3M vs $6.5M YoY; R&D expense $3.5M (-9% YoY), G&A $2.2M (-31% YoY).
- FDA cleared IND for NPM-119 (six-month GLP-1 implant for type 2 diabetes) in June 2024.
- First-in-human LIBERATE-1 study for NPM-115 (obesity implant) expected to start Q4 2024 in Australia, data in 2025.
- Veterinary GLP-1 implant data published in BMC Veterinary Research; 40% of domestic cats overweight.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/0001753926-24-001422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/vani-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer